Inhibition of mutant FLT3 receptors in leukemia cells by the small molecule tyrosine kinase inhibitor PKC412

Cancer Cell

Volumn 1, Issue 5, 2002, Pages 433-443

  Weisberg, Ellen ^a   Boulton, Christina ^a   Kelly, Louise M ^a   Manley, Paul ^b   Fabbro, Doriano ^b   Meyer, Thomas ^b   Gilliland, D Gary ^a   Griffin, James D ^a  

^a HARVARD MEDICAL SCHOOL   (United States)

^b NOVARTIS PHARMA AG   (Switzerland)

Author keywords

[No Author keywords available]

Indexed keywords

MIDOSTAURIN; ANTINEOPLASTIC AGENT; CD135 ANTIGEN; DRUG DERIVATIVE; ENZYME INHIBITOR; FLT3 PROTEIN, HUMAN; FLT3 PROTEIN, MOUSE; IMATINIB; INTERLEUKIN 3; ONCOPROTEIN; PROTEIN KINASE C; PROTEIN TYROSINE KINASE; PYRIMIDINE DERIVATIVE; STAUROSPORINE;

ACUTE GRANULOCYTIC LEUKEMIA; ANIMAL CELL; ANIMAL EXPERIMENT; ANIMAL TISSUE; APOPTOSIS; ARTICLE; GENE IDENTIFICATION; GENE MUTATION; GENE OVEREXPRESSION; HUMAN; HUMAN CELL; LEUKEMIA CELL; MOUSE; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RECEPTOR BINDING; ANIMAL; BAGG ALBINO MOUSE; BONE MARROW CELL; BONE MARROW TRANSPLANTATION; CELL CULTURE; CELL CYCLE; CELL DIVISION; CELL TRANSFORMATION; DRUG ANTAGONISM; DRUG EFFECT; DRUG RESISTANCE; ENZYMOLOGY; FLOW CYTOMETRY; GENETIC TRANSFECTION; GENETICS; IMMUNOBLOTTING; MALE; METABOLISM; MUTATION; NUDE MOUSE; PATHOLOGY; PHOSPHORYLATION;

ANIMALS; ANTINEOPLASTIC AGENTS; APOPTOSIS; BONE MARROW CELLS; BONE MARROW TRANSPLANTATION; CELL CYCLE; CELL DIVISION; CELL TRANSFORMATION, NEOPLASTIC; DRUG RESISTANCE, NEOPLASM; ENZYME INHIBITORS; FLOW CYTOMETRY; FMS-LIKE TYROSINE KINASE 3; HUMANS; IMMUNOBLOTTING; INTERLEUKIN-3; LEUKEMIA, MYELOCYTIC, ACUTE; MALE; MICE; MICE, INBRED BALB C; MICE, NUDE; MUTATION; PHOSPHORYLATION; PROTEIN KINASE C; PROTO-ONCOGENE PROTEINS; PYRIMIDINES; RECEPTOR PROTEIN-TYROSINE KINASES; STAUROSPORINE; TRANSFECTION; TUMOR CELLS, CULTURED;

EID: 0036595143     PISSN: 15356108     EISSN: None     Source Type: Journal    
DOI: 10.1016/S1535-6108(02)00069-7     Document Type: Article

References (36)

1. Allebach, J., Levis, M., Fai-Tse, K., Jones-Bolin, S., Ruggeri, B., Dionne, C., and Small, D. (2001). FLT3-targeted tyrosine kinase inhibitors inhibit proliferation, induce apoptosis, and improve survival in a murine leukemia model utilizing FLT3/ITD-transformed cells. Blood 98, 118a.
2. Bonnet, D., and Dick, J.E. (1997). Human acute myeloid leukemia is organized as a hierarchy that originates from a primitive hematopoietic cell. Nat. Med. 3, 730-737.
3. Daley, G., and Baltimore, D. (1988). Transformation of an interleukin-3-dependent hematopoietic cell line by the chronic myelogenous leukemia-specific p210 BCR/ABL protein. Proc. Natl. Acad. Sci. USA 85, 9312-9316.
4. Dehmel, U., Zaborski, M., Meierhoff, G., Rosnet, O., Birnbaum, D., Ludwig, W.D., Quentmeier, H., and Drexler, H.G. (1996). Effects of FLT3 ligand on human leukemia cells. I. Proliferative response of myeloid leukemia cells. Leukemia 10, 261-270.
5. Fabbro, D., Ruetz, S., Bodis, S., Pruschy, M., Csermak, K., Man, A., Campochiaro, P., Wood, J., O'Reilly, T., and Meyer, T. (2000). PKC412-a protein kinase inhibitor with a broad therapeutic potential. Anticancer Drug Des. 15, 17-28.
6. Fenski, R., Flesch, K., Serve, S., Mizuki, M., Oelmann, E., Kratz-Albers, K., Kienast, J., Leo, R., Schwartz, S., Berdel, W.E., and Serve, H. (2000). Constitutive activation of FLT3 in acute myeloid leukaemia and its consequences for growth of 32D cells. Br. J. Haematol. 108, 322-330.
7. Hayakawa, F., Towatari, M., Kiyoi, H., Tanimoto, M., Kitamura, T., Saito, H., and Naoe, T. (2000). Tandem-duplicated FLT3 constitutively activates STAT5 and MAP kinase and introduces autonomous cell growth in IL-3-dependent cell lines. Oncogene 19, 624-631.
8. Homann, S., Schacher, B., Zumstein-Mecker, S., Fabbro, D., Bold, G., and Ferrari, S. (2001). Expression and purification of human recombinant GST-FGF Receptor-1. J. Biotech. 86, 51-58.
9. Horiike, S., Yokota, S., Nakao, M., Iwai, T., Sasai, Y., Kaneko, H., Taniwaki, M., Kashima, K., Fujii, H., Abe, T., and Misawa, S. (1997). Tandem duplications of the FLT3 receptor gene are associated with leukemic transformation of myelodysplasia. Leukemia 11, 1442-1446.
10. Iwai, T., Yokota, S., Nakao, M., Okamoto, T., Taniwaki, M., Onodera, N., Watanabe, A., Kikuta, A., Tanaka, A., Asami, K., et al. (1999). Internal tandem duplication of the FLT3 gene and clinical evaluation in childhood acute myeloid leukemia. The Children 's Cancer and Leukemia Study Group. Japan. Leukemia. 13, 38-43.
11. Kelly, L.M., Liu, Q., Kutok, J.L., Williams, I.R., Boulton, C.L., and Gilliland, D.G. (2002). FLT3 internal tandem duplication mutations associated with human acute myeloid leukemias induce myeloproliferative disease in a murine bone marrow transplant model. Blood 99, 310-318.
12. Kiyoi, H., Naoe, T., Yokota, S., Nakao, M., Minami, S., Kuriyama, K., Takeshita, A., Saito, K., Hasegawa, S., Shimodaira, S., et al. (1997). Internal tandem duplication of FLT3 associated with leukocytosis in acute promyelocytic leukemia. Leukemia Study Group of the Ministry of Health and Welfare (Kohseisho). Leukemia 11, 1447-1452.
13. Kiyoi, H., Towatari, M., Yokota, S., Hamaguchi, M., Ohno, R., Saito, H., and Naoe, T. (1998). Internal tandem duplication of the FLT3 gene is a novel modality of elongation mutation which causes constitutive activation of the product. Leukemia 12, 1333-1337.
14. Kiyoi, H., Naoe, T., Nakano, Y., Yokota, S., Minami, S., Miyawaki, S., Asou, N., Kuriyama, K., Jinnai, I., Shimazaki, C., et al. (1999). Prognostic implication of FLT3 and N-RAS gene mutations in acute myeloid leukemia. Blood 93, 3074-3080.
15. Kondo, M., Horibe, K., Takahashi, Y., Matsumoto, K., Fukuda, M., Inaba, J., Kato, K., Kojima, S., and Matsuyama, T. (1999). Prognostic value of internal tandem duplication of the FLT3 gene in childhood acute myelogenous leukemia. Med. Pediatr. Oncol. 33, 525-529.
16. Levis, M., Tse, K.F., Smith, B.D., Garrett, E., and Small, D. (2001a). A FLT3 tyrosine kinase inhibitor is selectively cytotoxic to acute myeloid leukemia blasts harboring FLT3 internal tandem duplication mutations. Blood 98, 885-887.
17. Levis, M.J., Allebach, J., Tse, K.F., Zheng, R., Baldwin, B., Smith, B.D., Jones-Bolin, S., Ruggeri, B., Dionne, C., and Small, D. (2001b). FLT3-targeted inhibitors kill FLT3-dependent modeled cells, leukemia-derived cells lines, and primary AML blasts in vitro and in vivo. Blood 98, 721a.
18. Liu, Q., Schwaller, J., Kutok, J., Cain, D., Aster, J.C., Williams, I.R., and Gilliland, D.G. (2000). Signal transduction and transforming properties of the TEL-TRKC fusions associated with t(12;15)(p13;q25) in congenital fibrosarcoma and acute myelogenous leukemia. EMBO J. 19, 1827-1838.
19. Minami, Y., Yamamoto, K., Kiyoi, H., Saito, H., and Naoe, T. (2001). Selective apoptosis of mutant FLT3-transformed leukemia cells by Hsp90-inhibitors. Blood 98, 118a.
20. Nakao, M., Yokota, S., Iwai, T., Kaneko, H., Horiike, S., Kashima, K., Sonoda, Y., Fujimoto, T., and Misawa, S. (1996). Internal tandem duplication of the FLT3 gene found in acute myeloid leukemia. Leukemia 10, 1911-1918.
21. O'Farrell, A.M., Abrams, T., Yuen, H., Ngai, T., Louie, S., Wong, L., Heinrich, M., Yee, K., Smolich, B., Murray, L., et al. (2001). SUGEN compounds SU5416 and SU11248 inhibit FLT3 activity: therapeutic application in AML. Blood 98, 118a.
22. Okuda, K., Golub, T.R., Gilliland, D.G., and Griffin, J.D. (1996). p210BCR/ABL, p190BCR/ABL, and TEL/ABL activate similar signal transduction pathways in hematopoietic cell lines. Oncogene 13, 1147-1152.
23. Olsson, I., Bergh, G., Ehinger, M., and Gullberg, U. (1996). Cell differentiation in acute myeloid leukemia. Eur. J. Haematol. 57, 1-16.
24. Pabst, T., Mueller, B.U., Harakawa, N., Schoch, C., Haferlach, T., Behre, G., Hiddemann, W., Zhang, D.E., and Tenen, D.G. (2001). AML1-ETO downregulates the granulocytic differentiation factor C/EBPalpha in t(8;21) myeloid leukemia. Nat. Med. 7, 444-451.
25. Propper, D.J., McDonald, A.C., Man, A., Thavasu, P., Balkwill, F., Braybrooke, J.P., Caponigro, F., Graf, P., Dutreix, C., Blackie, R., et al. (2001). Phase I and pharmacokinetic study of PKC412, an inhibitor of protein kinase C. J. Clin. Oncol. 19, 1485-1492.
26. Rombouts, W.J., Blokland, I., Lowenberg, B., and Ploemacher, R.E. (2000). Biological characteristics and prognosis of adult acute myeloid leukemia with internal tandem duplications in the FLT3 gene. Leukemia 14, 675-683.
27. Rosnet, O., and Birnbaum, D. (1993). Hematopoietic receptors of Class III Receptor-Type tyrosine kinases. Crit. Rev. Oncog. 4, 595-613.
28. Sattler, M., Salgia, R., Okuda, K., Uemura, N., Durstin, M.A., Pisick, E., Xu, G., Li, J.L., Prasad, K.V., and Griffin, J.D. (1996). The proto-oncogene product p120CBL and the adaptor proteins CRKL and c-CRK link c-ABL, p190BCR/ ABL and p210BCR/ABL to the phosphatidylinositol-3′ kinase pathway. Oncogene 12, 839-846.
29. Schwaller, J., Frantsve, J., Aster, J., Williams, I.R., Tomasson, M.H., Ross, T.S., Peeters, P., Van Rompaey, L., Van Etten, R.A., Ilaria, R., Jr., et al. (1998). Transformation of hematopoietic cell lines to growth-factor independence and induction of a fatal myelo- and lymphoproliferative disease in mice by retrovirally transduced TEL/JAK2 fusion genes. EMBO J. 17, 5321-5333.
30. Tanaka, T., Tanaka, K., Ogawa, S., Kurokawa, M., Mitani, K., Yazaki, Y., Shibata, Y., and Hirai, H. (1997). An acute myeloid leukemia gene, AML1, regulates transcriptional activation and hemopoietic myeloid cell differentiation antagonistically by two alternative spliced forms. Leukemia 1111, 299-302.
31. Tse, K.F., Novelli, E., Civin, C.I., Bohmer, F.D., and Small, D. (2001). Inhibition of FLT3-mediated transformation by use of a tyrosine kinase inhibitor. Leukemia 15, 1001-1010.
32. Weisberg, E., and Griffin, J.D. (2000). Mechanism of resistance to the ABL tyrosine kinase inhibitor STI571 in BCR/ABL-transformed hematopoietic cell lines. Blood 95, 3498-3505.
33. Xu, F., Taki, T., Yang, H.W., Hanada, R., Hongo, T., Ohnishi, H., Kobayashi, M., Bessho, F., Yanagisawa, M., and Hayashi, Y. (1999). Tandem duplication of the FLT3 gene is found in acute lymphoblastic leukaemia as well as acute myeloid leukaemia but not in myelodysplastic syndrome or juvenile chronic myelogenous leukaemia in children. Br. J. Haematol. 105, 155-162.
34. Yamamoto, Y., Kiyoi, H., Nakano, Y., Suzuki, R., Kodera, Y., Miyawaki, S., Asou, N., Kuriyama, K., Yagasaki, F., Shimazaki, C., et al. (2001). Activating mutation of D835 within the activation loop of FLT3 in human hematologic malignancies. Blood 97, 2434-2439.
35. Yee, K.W.H., O'Farrell, A.M., Smolich, B.D., Cherrington, J.M., Wait, C.L., Griffith, D.J., McGreevey, L.S., and Heinrich, M.C. (2001). SU5416 and SU5614 inhibit wild-type and activated mutant FLT3 signaling in leukemia cells. Blood 98, 838a.
36. Zhao, M., Kiyoi, H., Yamamoto, Y., Ito, M., Towatari, M., Omura, S., Kitamura, T., Ueda, R., Saito, H., and Naoe, T. (2000). In vivo treatment of mutant FLT3-transformed murine leukemia with atyrosine kinase inhibitor. Leukemia 14, 374-378.